Tevogen Bio Highlights Promising Trial Data as CEO Leads Patient Advocacy at Capitol Hill, Pledging to Leverage Multi-Billion Dollar Company Assets to Combat Long COVID and Spearhead a New Wave of Medical Innovation

The primary study endpoints were related to safety. No dose-limiting toxicities or significant adverse events related to TVGN 489, including Cytokine Release Syndrome, were observed in any patient at any dose level. Endpoints measuring the reduction of viral load and the presence of cellular and humoral antiCOVID-19 responses after treatment were met. Fifty percent (50%) of treatment arm patients were immunocompromised versus six percent (6%) of observational arm patients. Treatment arm patients were infect ...